Syngene International Welcomes Peter Bains As CEO; Jonathan Hunt Steps Down As MD & CEO

Peter Bains has been appointed as the Chief Executive Officer, designate (Non-Key Managerial Personnel) of Syngene International Limited with effect from February 10, 2025.

Jonathan Hunt resigns from the position of Managing Director, Chief Executive Officer (MD & CEO), and Key Managerial Personnel (KMP) of the company to pursue new opportunities with effect from the above-said date.

Peter Bains has over 30 years of experience, he has held leadership roles at the Board, CEO, and senior corporate levels across various biopharmaceutical sectors, including biotech, vaccines, branded generics, life sciences, and CROs. Currently serving as Group CEO of Biocon Group, he was previously CEO and Board Member of Syngene International. He also served as CEO of Sosei Group, a Japanese biopharmaceutical company. Earlier, he spent 23 years at GlaxoSmithKline, where he held roles such as Head of Global Marketing and Senior Vice President of Commercial Development for GSK’s International region. Bains holds a bachelor’s degree in science (combined honours in zoology and physiology) from the University of Sheffield, United Kingdom.